Alok A. Khorana, MD, selected to head up prestigious group of medical and scientific advisors to NBCA
Gaithersburg, MD, April 28, 2020 – The National Blood Clot Alliance (NBCA) is pleased to announce the appointment of Alok A. Khorana, MD, Professor of Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, as the new Chair of its prestigious Medical and Scientific Advisory Board (MASAB).
“It’s an honor to serve NBCA at a time when the clotting community is experiencing a spectrum of new challenges that require a sharpened focus on the public health impact of venous thromboembolism and life-threatening blood clots,” Dr. Khorana says. “My goal as MASAB Chair will be to ensure that the work we do as an advisory group aligns effectively with NBCA’s mission and contributes to improved understanding and care of all people affected by clotting and clotting disorders.”
Dr. Khorana is a widely recognized expert in venous thromboembolism (VTE) and cancer, and he serves as Chair of the American Society of Clinical Oncology (ASCO) Clinical Practice Guidelines Panel (CPGC) Pancreas Cancer Working Group, Co-Chair of ASCO CPGS’s Multisite Advisory Group, and Co-Chair of the ASCO Guidelines Panel on Resectable Pancreas Cancer. He also is Past Chair of the ASCO CPGC Clinical Practice Guidelines Panel, and served or serves on the ASCO Scientific Program Committee and multiple Guidelines/Guidance Panels, including those of ASCO, American Society of Hematology, American Society for Radiation Oncology, and International Society on Thrombosis and Haemostasis,
“We’re tremendously fortunate to have Dr. Khorana step up to lend his time and expertise to MASAB in the guidance of NBCA’s efforts,” says Leslie Lake, President of NBCA’s Board of Directors. “The clinical oversight provided by MASAB has always served a crucial role in NBCA’s work, and under Dr. Khorana’s leadership we look forward to expanding the value and impact of the group to further advance our mission.”
Dr. Khorana, who was awarded the Cleveland Clinic’s Maria and Sam Miller Professional Excellence Award for Scientific Achievement in Clinical Research, has been published in a variety of journals, including New England Journal of Medicine, Journal of American Medical Association (JAMA), Journal of Clinical Oncology, Blood, Journal of the National Cancer Institute, Clinical Cancer Research, PLoS One, and JAMA Internal Medicine. He also has co-authored chapters in multiple textbooks, including Cecil Essentials of Medicine and DeVita’s Cancer: Principles and Practice of Oncology. He also is co-editor of the book Cancer-Associated Thrombosis: New Findings in Translational Science, Prevention and Treatment (Informa, 2007).
As Chair of MASAB, Dr. Khorana also now assumes a seat on NBCA’s Board of Directors, acting as MASAB liaison with NBCA’s volunteer lay leadership, and also working with the organization’s senior staff as programs and services provided by NBCA are designed and implemented.
With his appointment, Dr. Khorana now succeeds NBCA’s previous MASAB Chair, Michael Streiff, MD, FACP, Professor of Medicine, Johns Hopkins Medical Institutions, Baltimore, Maryland. Members of NBCA’s Board of Directors, MASAB, and NBCA staff extend their deepest appreciation to Dr. Streiff for the six years he dedicated his time and applied his vast expertise in VTE to supporting the work of the organization.
NBCA, a 501(c)(3), non-profit, voluntary health organization, is dedicated to advancing the prevention, early diagnosis, and successful treatment of life-threatening blood clots, such as deep vein thrombosis, pulmonary embolism and clot-provoked stroke. NBCA works on behalf of people who may be susceptible to blood clots, including, but not limited to, people with clotting disorders, atrial fibrillation, cancer, traumatic injury, and risks related to surgery, lengthy immobility, child birth, and birth control. NBCA accomplishes its mission through programs that build public awareness, educate patients and healthcare professionals, and promote supportive public and private sector policy.